Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

Eric M. Reiman, Kewei Chen, Xiaofen Liu, Daniel Bandy, Meixiang Yu, Wendy Lee, Napatkamon Ayutyanont, Jennifer Keppler, Stephanie A. Reeder, Jessica B S Langbaum, Gene E. Alexander, William E. Klunk, Chester A. Mathis, Julie C. Price, Howard J. Aizensteini, Steven T. DeKosky, Richard John Caselli

Research output: Contribution to journalArticle

516 Citations (Scopus)

Abstract

Fibrillar amyloid-beta (Aβ) is found in the brains of many cogni-tively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.

Original languageEnglish (US)
Pages (from-to)6820-6825
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number16
DOIs
StatePublished - Apr 21 2009

Fingerprint

Amyloid
Alzheimer Disease
Apolipoprotein E4
Homozygote
Parietal Lobe
Gyrus Cinguli
Primary Prevention
Heterozygote
Basal Ganglia
Positron-Emission Tomography
Genes
Biomarkers
Alleles
Brain

Keywords

  • Apolipoprotein E
  • Pittsburgh compound B pet

ASJC Scopus subject areas

  • General

Cite this

Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. / Reiman, Eric M.; Chen, Kewei; Liu, Xiaofen; Bandy, Daniel; Yu, Meixiang; Lee, Wendy; Ayutyanont, Napatkamon; Keppler, Jennifer; Reeder, Stephanie A.; Langbaum, Jessica B S; Alexander, Gene E.; Klunk, William E.; Mathis, Chester A.; Price, Julie C.; Aizensteini, Howard J.; DeKosky, Steven T.; Caselli, Richard John.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 16, 21.04.2009, p. 6820-6825.

Research output: Contribution to journalArticle

Reiman, EM, Chen, K, Liu, X, Bandy, D, Yu, M, Lee, W, Ayutyanont, N, Keppler, J, Reeder, SA, Langbaum, JBS, Alexander, GE, Klunk, WE, Mathis, CA, Price, JC, Aizensteini, HJ, DeKosky, ST & Caselli, RJ 2009, 'Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 16, pp. 6820-6825. https://doi.org/10.1073/pnas.0900345106
Reiman, Eric M. ; Chen, Kewei ; Liu, Xiaofen ; Bandy, Daniel ; Yu, Meixiang ; Lee, Wendy ; Ayutyanont, Napatkamon ; Keppler, Jennifer ; Reeder, Stephanie A. ; Langbaum, Jessica B S ; Alexander, Gene E. ; Klunk, William E. ; Mathis, Chester A. ; Price, Julie C. ; Aizensteini, Howard J. ; DeKosky, Steven T. ; Caselli, Richard John. / Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 16. pp. 6820-6825.
@article{235662bd5f874d1f8b1fd923e47804e6,
title = "Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease",
abstract = "Fibrillar amyloid-beta (Aβ) is found in the brains of many cogni-tively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.",
keywords = "Apolipoprotein E, Pittsburgh compound B pet",
author = "Reiman, {Eric M.} and Kewei Chen and Xiaofen Liu and Daniel Bandy and Meixiang Yu and Wendy Lee and Napatkamon Ayutyanont and Jennifer Keppler and Reeder, {Stephanie A.} and Langbaum, {Jessica B S} and Alexander, {Gene E.} and Klunk, {William E.} and Mathis, {Chester A.} and Price, {Julie C.} and Aizensteini, {Howard J.} and DeKosky, {Steven T.} and Caselli, {Richard John}",
year = "2009",
month = "4",
day = "21",
doi = "10.1073/pnas.0900345106",
language = "English (US)",
volume = "106",
pages = "6820--6825",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "16",

}

TY - JOUR

T1 - Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

AU - Reiman, Eric M.

AU - Chen, Kewei

AU - Liu, Xiaofen

AU - Bandy, Daniel

AU - Yu, Meixiang

AU - Lee, Wendy

AU - Ayutyanont, Napatkamon

AU - Keppler, Jennifer

AU - Reeder, Stephanie A.

AU - Langbaum, Jessica B S

AU - Alexander, Gene E.

AU - Klunk, William E.

AU - Mathis, Chester A.

AU - Price, Julie C.

AU - Aizensteini, Howard J.

AU - DeKosky, Steven T.

AU - Caselli, Richard John

PY - 2009/4/21

Y1 - 2009/4/21

N2 - Fibrillar amyloid-beta (Aβ) is found in the brains of many cogni-tively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.

AB - Fibrillar amyloid-beta (Aβ) is found in the brains of many cogni-tively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.

KW - Apolipoprotein E

KW - Pittsburgh compound B pet

UR - http://www.scopus.com/inward/record.url?scp=66149084048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149084048&partnerID=8YFLogxK

U2 - 10.1073/pnas.0900345106

DO - 10.1073/pnas.0900345106

M3 - Article

C2 - 19346482

AN - SCOPUS:66149084048

VL - 106

SP - 6820

EP - 6825

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 16

ER -